91¹ú²úÊÓƵ

Our current studies and a brief description of each are listed below. More information about these studies, including eligibility criteria, funding sources, and team members involved, can be found by clicking the study’s name.

Current Studies

CRAVE Support: Measuring and Intervening Craving Moments in Substance Use Disorders (SUD) Using Bio-Behavioral Sensors
The CRAVE study aims to gather data from individuals struggling with opioid use disorder to explore the potential use of wearable devices in preventing instances of cravings in the future.

KINECT-Next: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia
This study is being conducted to find out whether an investigational drug may help reduce symptoms in people with a psychiatric condition who are experiencing sudden, irregular movements known as tardive dyskinesia (TD). The study will also evaluate the investigational drug’s safety and monitor for any potential side effects.

AMPA-NOVA 1: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
The purpose of this 12–14–week study is to look at whether the study drug, NBI-1065845, works to improve depression symptoms when taken with your current antidepressants. You can take part in this study if you are currently on antidepressants that are not working well enough. The study drug will be compared with a placebo (which looks like the study drug but contains no active ingredients).

AMPA Vega 2: A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
The purpose of this research study is to find out if the investigational study drug (NBI-1065845) is safe to be given for a longer period of time to those with depression. The study will last for 158 to 162 weeks.

Norlight: A Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of ACP-211 Monotherapy in Adults With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
This clinical research study is testing a new investigational drug, taken under supervision, to see if it can help reduce depression symptoms in people who are not receiving adequate symptom relief from their current antidepressant.

OARS 7: A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms
The purpose of this two-part study is to see if a drug called seltorexant (JNJ-42847922) added to your current antidepressant treatment would help to improve your depression and your sleep problems (such as difficulty falling asleep, staying asleep, waking up too early or otherwise poor-quality sleep).